0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessAlthough the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.
Kiwamu Okita, Namiki Izumi, Osamu Matsui, Katsuaki Tanaka, Shuichi Kaneko, Hisataka Moriwaki, Kenji Ikeda, Yukio Osaki, Kazushi Numata, Kohei Nakachi, Norihiro Kokudo, Kazuho Imanaka, Shuhei Nishiguchi, Takuji Okusaka, Yoichi Nishigaki, Susumu Shiomi, Masatoshi Kudo, Kenichi Ido, Yoshiyasu Karino, Norio Hayashi, Yasuo Ohashi, Masatoshi Makuuchi, Hiromitsu Kumada (2014). Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. , 50(2), DOI: https://doi.org/10.1007/s00535-014-0956-9.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2014
Authors
23
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1007/s00535-014-0956-9
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
